General Medical Devices

Nipro Corporation

Nipro Reports Earnings Per Share Far Below Expectations

8086

Nipro Corporation's Board of Directors has decided to acquire full ownership of G2/Spryte Holdco, LLC, currently holding 39% of the company. The acquisition aims to enhance Nipro's strategic position and support long-term growth, with the transaction set to begin on December 19, 2025. The financial implications are still under review, with further disclosures expected if necessary.

Reuters

Nipro to Acquire Full Ownership of G2/Spryte Holdco

Nipro Corporation has renamed its subsidiary Nipro Holdings Americas, Inc. to Nipro Americas Group Companies, Inc., effective August 1, 2025. This change reflects the importance of the Americas in NIPRO's global strategy, enhancing regional governance and compliance. The Miami-based subsidiary will support business operations across North and Latin America, aligning with NIPRO's goal to improve responsiveness to market needs. This announcement emphasizes the region's role as a key contributor to the company's overseas sales.

Nipro Holdings Americas Changes Name to Nipro Americas Group Companies, Strengthening Regional Governance

Nipro Medical Corporation, a subsidiary of Nipro Corporation, reported an internal information leak on June 19, 2025. The company is taking steps to block external access and assess the incident's scope and impact. Nipro has apologized for any concerns caused and is investigating the cause to prevent future occurrences. The potential impact on business performance is also under review, with material developments to be disclosed promptly.

Information Leak Detected at Nipro Medical Corporation, Subsidiary of Nipro Corporation

Samsung Biologics subsidiary Samsung Bioepis signed a licensing and commercialization agreement with Japan's Nipro Corporation to bring several biosimilar candidates, including SB17, a ustekinumab biosimilar, to Japan. Under the agreement, Samsung Bioepis will oversee development, manufacturing, and supply, while NIPRO will handle commercialization in Japan, Samsung Bioepis said in a Monday press release. The partnership aims to expand Samsung Bioepis' presence in Japan and improve access to cost-effective biologic treatments, it said.

Trading View

Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan

Nipro Corporation Announces Toshinobu Morimoto as New Audit & Supervisory Board Member Nipro Corporation has announced a new candidate for its Audit & Supervisory Board Member position. Toshinobu Morimoto, formerly the Executive Officer and Chief Audit Executive of the Internal Audit Office, is set to assume the role of Full-time Audit & Supervisory Board Member. This change is scheduled for approval at the Annual General Meeting of Shareholders on June 26, 2025.

Nipro Corporation Announces Toshinobu Morimoto as New Audit & Supervisory Board Member

Nipro Corporation's recent earnings report revealed a significant miss in earnings per share (EPS), falling 71% short of analyst expectations at JP¥31.36, while revenues were in line at JP¥645b. Analysts now forecast a 2.2% revenue growth to JP¥658.6b for 2026, but EPS estimates dropped substantially to JP¥78.11. The consensus price target remains unchanged at JP¥1,360, indicating mixed analyst sentiment. Nipro's expected growth lags behind the industry average, raising concerns about future performance amid identified investment risks.

Simplywall

Nipro Corporation Just Missed EPS By 71%: Here's What Analysts Think Will Happen Next

Nipro Corporation (TSE:8086) has announced an increase in its dividend to ¥20.00, yielding 2.4%. However, concerns arise regarding the sustainability of this payment, as the dividend has previously constituted a large portion of earnings without generating cash flow. Despite a projected 19.3% rise in earnings per share, the payout ratio may reach 83%, indicating potential risks. Nipro's dividend history shows fluctuations, with a CAGR of 1.9% since 2015. Overall, while the dividend is raised, its sustainability remains questionable, and the company is not considered a top income stock.